Eisai Overview

  • Year Founded
  • 1941

Year Founded

  • Status
  • Public

  • Employees
  • 10,543

Employees

  • Stock Symbol
  • 4523

Stock Symbol

  • Investments
  • 39

  • Share Price
  • $33.30
  • (As of Thursday Closing)

Eisai General Information

Description

Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Contact Information

Website
www.eisai.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 4-6-10 Koishikawa
  • Tokyo, Bunkyo-ku 112-8088
  • Japan
+81
Primary Industry
Pharmaceuticals
Stock Exchange
TKS
Vertical(s)
Corporate Office
  • 4-6-10 Koishikawa
  • Tokyo, Bunkyo-ku 112-8088
  • Japan
+81

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eisai Stock Performance

As of 19-Nov-2026, Eisai’s stock price is $33.30. Its current market cap is $9.4B with 282M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$33.30 $32.85 $22.80 - $33.64 $9.4B 282M 1.26M $0.99

Eisai Financials Summary

As of 30-Sep-2026, Eisai has a trailing 12-month revenue of $5.69B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 8,488,036 8,192,563 7,486,902 11,130,507
Revenue 5,688,806 5,476,055 5,176,457 5,133,586
EBITDA 570,904 555,237 618,257 642,294
Net Income 278,688 255,817 304,482 293,495
Total Assets 9,685,184 9,065,002 9,265,739 9,209,112
Total Debt 1,619,549 1,164,039 1,253,141 1,053,221
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Eisai Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Eisai‘s full profile, request access.

Request a free trial

Eisai Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and deve
Pharmaceuticals
Tokyo, Japan
10,543 As of 2026

Mumbai, India
 

London, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eisai Competitors (23)

One of Eisai’s 23 competitors is Evonile Pharma, a Private Equity-Backed company based in Mumbai, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Evonile Pharma Private Equity-Backed Mumbai, India
GSK Corporation London, United Kingdom
China Resources Pharmaceutical Group Corporation Hong Kong, Hong Kong
Novartis Corporation Basel, Switzerland
Roche Corporation Basel, Switzerland
You’re viewing 5 of 23 competitors. Get the full list »

Eisai Patents

Eisai Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026197354-A1 Anti-transferrin receptor antibody Pending 21-Mar-2025
US-20260297208-A1 Bispecific antibody Pending 21-Mar-2025
WO-2026197356-A1 Bispecific antibody Pending 21-Mar-2025
WO-2026169921-A1 Combination therapies comprising eribulin-based antibody-drug conjugates Pending 06-Feb-2025
WO-2026152108-A1 Systems and methods for predicting cognitive impairment progression in individuals with preclinical alzheimer's disease Pending 13-Jan-2025 G16B40/20
To view Eisai’s complete patent history, request access »

Eisai Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eisai Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Eisai‘s full profile, request access.

Request a free trial

Eisai Investments & Acquisitions (39)

Eisai’s most recent deal was a Later Stage VC with Beren Therapeutics for . The deal was made on 10-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Beren Therapeutics 10-Jun-2026 Later Stage VC Drug Discovery
VIVACTA Biotechnology 26-Jan-2026 Early Stage VC Drug Discovery
Seed Therapeutics 01-Aug-2025 Later Stage VC Drug Discovery
EcoNaviSta 07-May-2025 Merger/Acquisition Medical Records Systems
Periotherapia 31-Jan-2025 Later Stage VC Drug Discovery
You’re viewing 5 of 39 investments and acquisitions. Get the full list »

Eisai ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

24.72 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Eisai’s complete esg history, request access »

Eisai Exits (9)

Eisai’s most recent exit was on 09-Jan-2025 from Numab Therapeutics. The exit was categorized as with 10 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Numab Therapeutics 09-Jan-2025 Completed
  • 10 buyers
PRISM BioLab 24-Jan-2024 Completed
  • 3 buyers
Allm 05-Apr-2021 Completed
  • 19 buyers
Caraway Therapeutics 26-Nov-2018 Completed
  • 8 buyers
Voluntis 01-Apr-2018 Later Stage VC Completed
  • 3 buyers
You’re viewing 5 of 9 exits. Get the full list »

Eisai Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Eisai Ventures Tokyo, Japan 2019
Eisai Innovation Cambridge, MA 2019

Eisai FAQs

  • When was Eisai founded?

    Eisai was founded in 1941.

  • Where is Eisai headquartered?

    Eisai is headquartered in Tokyo, Japan.

  • What is the size of Eisai?

    Eisai has 10,543 total employees.

  • What industry is Eisai in?

    Eisai’s primary industry is Pharmaceuticals.

  • Is Eisai a private or public company?

    Eisai is a Public company.

  • What is Eisai’s stock symbol?

    The ticker symbol for Eisai is 4523.

  • What is the current stock price of Eisai?

    As of 19-Nov-2026 the stock price of Eisai is $33.30.

  • What is the current market cap of Eisai?

    The current market capitalization of Eisai is $9.4B.

  • What is Eisai’s current revenue?

    The trailing twelve month revenue for Eisai is $5.69B.

  • Who are Eisai’s competitors?

    Evonile Pharma, GSK, China Resources Pharmaceutical Group, Novartis, and Roche are some of the 23 competitors of Eisai.

  • What is Eisai’s annual earnings per share (EPS)?

    Eisai’s EPS for 12 months was $0.99.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process